Ziftomenib not checked

Kura Oncology, Inc. · KO-539

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
8 active
8 in total · 5 in the EU
Targets
 

What this is

How it works
Menin Inhibitor FDA class
Tested for
Acute Myeloid Leukemia (3 trials), Acute Myeloid Leukemia (AML) (2 trials), AML With Mutated NPM1 (2 trials), KMT2Ar (2 trials), NPM1 Mutation (2 trials), Advanced Malignant Neoplasm, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia and 24 more
Main trialPhase 3
“Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the…”In the company’s words, NCT07007312 on ClinicalTrials.gov
Other names
KO-539

Other drugs for Acute Myeloid Leukemia

All 140 drugs for Acute Myeloid Leukemia

Coming up7

Changes1

Last 90 days

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Nov 2031 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 2Recruiting Mar 2027 A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Phase 1/2Active, not recruiting 16 Oct 2028 First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1Recruiting Dec 2026 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1Not yet recruiting 28 Feb 2029 Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Phase 1Recruiting Jun 2029 A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Phase 1Recruiting Apr 2030 A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1Authorised not given A Phase 1 Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ziftomenib

Following is part of Solo: you see every change to Ziftomenib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in